Challenges facing China's pharmaceutical industry; "quality will improve," AEI says

The growing importance of China as a center for global pharmaceutical manufacturing makes deadly lapses in quality a concern worldwide,  according to a report by the American Enterprise Institute, a Washington  DC-based conservative-oriented think-tank.

Roger Bate, lead author of a recent outlook paper for the Institute,  titled the Problems and Potential of China's Pharmaceutical Industry,  discussed some of the issues raised by the report with the Marketletter.  Among these are the Chinese government's "inattention," which provides  the opportunity for counterfeit and substandard medicine production  and distribution, efforts by the regulators to address the problems and  ways in which international partners, including the private sector, can  help improve standards.